Alvotech (ALVO) Asset Writedowns and Impairment (2021 - 2026)
Alvotech (ALVO) posted Asset Writedowns and Impairment of $3.1 million for Q1 2026, up 135.09% on a QoQ basis from -$8.7 million in Q4 2025, and up 345.63% year-over-year from $686000.0 in Q1 2025.
Alvotech (ALVO) Asset Writedowns and Impairment (2021 - 2026) Analysis & Trends
Alvotech's Asset Writedowns and Impairment history runs 5 years deep, the most recent figure standing at $3.1 million for Q1 2026.
- Quarterly Asset Writedowns and Impairment rose 345.63% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (up 349.84% YoY) and the FY2023 annual result came in at $21.5 million, changed N/A from the prior year.
- Asset Writedowns and Impairment was $3.1 million for Q1 2026 at Alvotech, up from -$8.7 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $27.3 million in Q4 2022 and bottomed at -$8.7 million in Q4 2025.
- A 4-year average of $2.2 million and a median of $686000.0 in 2025 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2022 — Asset Writedowns and Impairment soared 43450.79% — and 2025, when it sank 150.16%.
- Alvotech's Asset Writedowns and Impairment stood at $27.3 million in 2022, then tumbled by 112.75% to -$3.5 million in 2024, then sank by 150.16% to -$8.7 million in 2025, then soared by 135.09% to $3.1 million in 2026.
- Business Quant data shows ALVO's Asset Writedowns and Impairment at $3.1 million in Q1 2026, -$8.7 million in Q4 2025, and $3.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Alvotech | 907.91 Mn | 907.91 Mn | 5.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.06 Mn |
| Mar 31, 2026 | 3.06 Mn |
| Dec 31, 2025 | -8.71 Mn |
| Dec 31, 2025 | -8.71 Mn |
| Sep 30, 2025 | 3.48 Mn |
| Sep 30, 2025 | 3.48 Mn |
| Jun 30, 2025 | 4.55 Mn |
| Jun 30, 2025 | 4.55 Mn |
| Mar 31, 2025 | 686,000.00 |
| Mar 31, 2025 | 686,000.00 |
| Dec 31, 2024 | -3.48 Mn |
| Dec 31, 2024 | -3.48 Mn |
| Sep 30, 2024 | 3.41 Mn |
| Sep 30, 2024 | 3.41 Mn |
| Jun 30, 2024 | -1.56 Mn |
| Jun 30, 2024 | -1.56 Mn |
| Mar 31, 2024 | -5.38 Mn |
| Mar 31, 2024 | -5.38 Mn |
| Dec 31, 2022 | 27.31 Mn |
| Dec 31, 2022 | 27.31 Mn |